Efficacy and safety of short-term edaravone or nerve growth factor add-on therapy for alcohol-related brain damage: A multi-centre randomised control trial.

Hongxuan WangLei LiuXuhui ZhouYanzhong GuanYanfei LiPeiyun ChenRanran DuanWeibian YangXiaoming RongChengji WuJianzhong YangMei YangYanjie JiaJian HuXiaofeng ZhuYing Peng

Published in: Addiction (Abingdon, England) (2023)

The short-term addition of edaravone to supplementary therapy treatment for alcohol-related brain damage (ARBD) improved executive cognitive function in patients with ARBD.

Keyphrases

growth factor
resting state
white matter
oxidative stress
clinical trial
alcohol consumption
open label
functional connectivity
cerebral ischemia
multiple sclerosis
stem cells
working memory
mesenchymal stem cells
placebo controlled